[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100574676":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":11,"locations":21,"responsibleParty":39,"collaborators":41,"id":45,"slug":10,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":46,"sex":52,"minAge":53,"maxAge":10,"enrollmentInfo":54,"targetDuration":57,"studyType":58,"phases":10,"briefSummary":59,"conditions":60,"keywords":10,"overallStatus":24,"whyStopped":10,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},{"fullName":5,"class":6},"European Institute of Oncology","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":10},"patient with metastatic prostate cancer (mPC)",null,[12,17],{"name":13,"role":14,"phone":15,"phoneExt":10,"email":16},"Elena Guerini Rocco, MD","CONTACT","00390294372871","elena.guerinirocco@ieo.it",{"name":18,"role":14,"phone":19,"phoneExt":10,"email":20},"francesca lombardi, biologist","00390257489425","francesca.lombardi@ieo.it",[22],{"facility":23,"status":24,"city":25,"state":26,"zip":27,"country":26,"countryCode":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":35},"European Institute of oncology","RECRUITING","Milan","Italy","20141","IT",{"type":30,"coordinates":31},"Point",[32,33],9.18951,45.46427,{"lat":33,"lon":32},[36],{"name":37,"role":14,"phone":38,"phoneExt":10,"email":16},"elena Guerini Rocco, MD","+300294372871",{"type":40,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[42],{"name":43,"class":44},"Pfizer","INDUSTRY","100574676",false,"NCT06762379","Implementation of a New Algorithm for HRR Gene Mutation Testing in Patients With mPC Through Liquid Biopsy Integration","Implementation of a New Algorithm for HRR Gene Mutation Testing in Patients With mPC","L2-267","Inclusion Criteria:\n\n* Patients with metastatic prostate cancer whose tumor tissue is unavailable or inadequate for molecular testing. • Written informed consent must be signed and dated by the patient and the investigator prior to inclusion.\n\nExclusion Criteria:\n\n* Unable to provide written informed consent","MALE","18 Years",{"count":55,"type":56},125,"ESTIMATED","36 Months","OBSERVATIONAL","Implementation of a new algorithm for HRR gene mutation testing in patients with mPC through liquid biopsy integration",[61],"Metastatic Prostate Cancer (mPC)","2026-03-23",{"date":64,"type":65},"2026-03-24","ACTUAL",{"date":67,"type":65},"2024-12-20",{"date":69,"type":56},"2030-12-31",{"name":5,"class":6},1]